Peter Thiel’s ‘Steroid Olympics’ Startup Wants to Sell You the Sketchy Peptides

This development highlights the growing intersection of biotech innovation and consumer access to experimental substances, raising important questions about regulation and safety. As startups venture into uncharted territory with banned peptides, both the tech industry and consumers must navigate potential ethical and health risks. It underscores the need for clearer policies and informed decision-making in the rapidly evolving biotech landscape.

• Startups are marketing experimental peptides banned by the FDA.
• This raises safety and regulatory concerns for consumers and the industry.
• The trend signals a push toward unregulated biotech products in the market.